Suppr超能文献

前列腺素在心脏和血管重构中的作用。

Prostanoids in Cardiac and Vascular Remodeling.

机构信息

Department of Systems Pharmacology and Translational Therapeutics (E.R., G.A.F.), University of Pennsylvania Perelman School of Medicine, Philadelphia.

Institute for Translational Medicine and Therapeutics (E.R., G.A.F.), University of Pennsylvania Perelman School of Medicine, Philadelphia.

出版信息

Arterioscler Thromb Vasc Biol. 2024 Mar;44(3):558-583. doi: 10.1161/ATVBAHA.123.320045. Epub 2024 Jan 25.

Abstract

Prostanoids are biologically active lipids generated from arachidonic acid by the action of the COX (cyclooxygenase) isozymes. NSAIDs, which reduce the biosynthesis of prostanoids by inhibiting COX activity, are effective anti-inflammatory, antipyretic, and analgesic drugs. However, their use is limited by cardiovascular adverse effects, including myocardial infarction, stroke, hypertension, and heart failure. While it is well established that NSAIDs increase the risk of atherothrombotic events and hypertension by suppressing vasoprotective prostanoids, less is known about the link between NSAIDs and heart failure risk. Current evidence indicates that NSAIDs may increase the risk for heart failure by promoting adverse myocardial and vascular remodeling. Indeed, prostanoids play an important role in modulating structural and functional changes occurring in the myocardium and in the vasculature in response to physiological and pathological stimuli. This review will summarize current knowledge of the role of the different prostanoids in myocardial and vascular remodeling and explore how maladaptive remodeling can be counteracted by targeting specific prostanoids.

摘要

前列腺素是由花生四烯酸经环氧化酶(COX)同工酶作用生成的具有生物活性的脂质。非甾体抗炎药(NSAIDs)通过抑制 COX 活性减少前列腺素的生物合成,是有效的抗炎、解热和镇痛药。然而,它们的使用受到心血管不良事件的限制,包括心肌梗死、中风、高血压和心力衰竭。虽然已经明确 NSAIDs 通过抑制血管保护前列腺素增加动脉粥样硬化血栓形成事件和高血压的风险,但关于 NSAIDs 与心力衰竭风险之间的联系知之甚少。目前的证据表明,NSAIDs 可能通过促进不良的心肌和血管重塑增加心力衰竭的风险。事实上,前列腺素在调节心肌和血管对生理和病理刺激发生的结构和功能变化方面发挥着重要作用。这篇综述将总结不同前列腺素在心肌和血管重塑中的作用,并探讨如何通过靶向特定前列腺素来对抗适应性重塑。

相似文献

1
Prostanoids in Cardiac and Vascular Remodeling.
Arterioscler Thromb Vasc Biol. 2024 Mar;44(3):558-583. doi: 10.1161/ATVBAHA.123.320045. Epub 2024 Jan 25.
2
Cardiovascular Biology of Prostanoids and Drug Discovery.
Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):1454-1463. doi: 10.1161/ATVBAHA.119.313234. Epub 2020 Apr 16.
3
Adverse effects of COX-2 inhibitors.
ScientificWorldJournal. 2005 Aug 18;5:629-45. doi: 10.1100/tsw.2005.82.
4
Anti-inflammatory drugs in the 21st century.
Subcell Biochem. 2007;42:3-27. doi: 10.1007/1-4020-5688-5_1.
5
Dual acting anti-inflammatory drugs: a reappraisal.
Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872.
6
Cardiovascular risk, hypertension, and NSAIDs.
Curr Rheumatol Rep. 2007 Apr;9(1):36-43. doi: 10.1007/s11926-007-0020-3.
8
Cyclooxygenase-2 inhibitors: a painful lesson.
Cardiovasc Hematol Disord Drug Targets. 2006 Jun;6(2):85-100. doi: 10.2174/187152906777441803.
9
Nonsteroidal anti-inflammatory drugs and heart failure.
Drugs. 2003;63(6):525-34. doi: 10.2165/00003495-200363060-00001.
10
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
Curr Pharm Des. 2007;13(22):2215-27. doi: 10.2174/138161207781368774.

引用本文的文献

1
NSAID overuse leading to cardiac aneurysm: Unveiling a missed diagnosis of Behçet's disease: A case report.
Medicine (Baltimore). 2025 Aug 22;104(34):e44111. doi: 10.1097/MD.0000000000044111.
3
Prostaglandins and the Cardiovascular System.
Arterioscler Thromb Vasc Biol. 2025 Jun;45(6):841-844. doi: 10.1161/ATVBAHA.124.320744. Epub 2025 May 21.
4
Targeting the E Prostanoid Receptor EP4 Mitigates Cardiac Fibrosis Induced by β-Adrenergic Activation.
Adv Sci (Weinh). 2025 Mar;12(12):e2413324. doi: 10.1002/advs.202413324. Epub 2025 Feb 7.
5
PAC1 Agonist Maxadilan Reduces Atherosclerotic Lesions in Hypercholesterolemic ApoE-Deficient Mice.
Int J Mol Sci. 2024 Dec 10;25(24):13245. doi: 10.3390/ijms252413245.
6
Epidemiology, risk factors and mechanism of breast cancer and atrial fibrillation.
Cardiooncology. 2024 Dec 23;10(1):92. doi: 10.1186/s40959-024-00298-y.
7
Molecular Thumbprints: Biological Signatures That Measure Loss of Identity.
Biomolecules. 2024 Oct 9;14(10):1271. doi: 10.3390/biom14101271.
8
Pain from Internal Organs and Headache: The Challenge of Comorbidity.
Diagnostics (Basel). 2024 Aug 12;14(16):1750. doi: 10.3390/diagnostics14161750.

本文引用的文献

1
Deep phenotyping of the lipidomic response in COVID-19 and non-COVID-19 sepsis.
Clin Transl Med. 2023 Nov;13(11):e1440. doi: 10.1002/ctm2.1440.
2
Microsomal prostaglandin E synthase-1 inhibition prevents adverse cardiac remodelling after myocardial infarction in mice.
Br J Pharmacol. 2023 Aug;180(15):1981-1998. doi: 10.1111/bph.16061. Epub 2023 Mar 10.
4
Prostaglandin E mediates the late phase of ischemic preconditioning in the heart via its receptor subtype EP.
Heart Vessels. 2023 Apr;38(4):606-613. doi: 10.1007/s00380-022-02219-4. Epub 2022 Dec 16.
8
Immunohistochemical analysis of MMP-9 and COX-2 expression in carotid atherosclerotic plaques among patients undergoing carotid endarterectomy: A prospective study.
J Stroke Cerebrovasc Dis. 2022 Nov;31(11):106731. doi: 10.1016/j.jstrokecerebrovasdis.2022.106731. Epub 2022 Sep 5.
9
The (rs1330344) CC Genotype Contributes to Susceptibility to Kawasaki Disease in Southern Chinese Children.
Angiology. 2023 Oct;74(9):832-839. doi: 10.1177/00033197221118343. Epub 2022 Sep 2.
10
PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2.
J Mol Cell Cardiol. 2022 Nov;172:63-77. doi: 10.1016/j.yjmcc.2022.07.012. Epub 2022 Aug 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验